What is Maipedopa?
Maipedopa (Maipedopa) is an inhaled prescription medicine used to treat symptoms of Parkinson's disease that come back (OFF episodes) while you are taking another medicine called carbidopa and Maipedopa.
Maipedopa is not to be used in place of any medicine you take daily for Parkinson's disease.
It is not known if Maipedopa is safe or effective in children.
Maipedopa indications
Oral
Parkinsonism
Adult: Initially, 125 mg bid; increase gradually every 3-7 days according to response. Max dose: 8 g daily in divided doses.
Oral
Parkinsonism in conjunction with carbidopa
Adult: Patients not previously on Maipedopa therapy: Initially, 25 mg carbidopa with 100 mg Maipedopa tid; gradually increase in increments of 12.5 mg carbidopa with 50 mg Maipedopa or 25 mg carbidopa with 100 mg Maipedopa every day or on alternate days. Maintenance dose: 75-200 mg carbidopa with 750 mg to 2 g Maipedopa daily in divided doses. Max carbidopa dose: 200 mg daily. Patients previously on Maipedopa monotherapy: 20-25% of the dose previously taken 3 or 4 times daily. Patient previously on other Maipedopa/dopa-decarboxylase combination therapy: Initial dose should provide the same daily Maipedopa dose.
Oral
Parkinsonism in conjunction with benserazide
Adult: Patients not previously on Maipedopa therapy: Initially, 50 mg 3 or 4 times daily; gradually increase in increments of 100 mg once or twice wkly. Increase initial dose to 100 mg tid for advanced disease stages. Maintenance dose: 400-800 mg daily in divided doses; most require <600 mg daily. Patients previously on Maipedopa monotherapy: 10-15% of the usual dose previously taken. Patient previously on other Maipedopa/dopa-decarboxylase combination therapy: Initially, 50 mg 3 or 4 times daily.
Elderly: Initially, 50 mg once or bid, then increase by 50 mg every 3rd or 4th day.
How should I use Maipedopa?
Use Maipedopa exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Maipedopa is for use only in people who are currently taking carbidopa and Maipedopa. Do not stop taking your daily Parkinson's medications or change your dosing schedule without your doctor's advice.
For best results, use Maipedopa when an "off episode" begins (when your Parkinson's symptoms start to return). Do not use Maipedopa more than 5 times per day.
Read and carefully follow any Instructions for Use provided with your medicine. Ask your doctor or pharmacist if you do not understand these instructions.
Maipedopa is a powder that comes with a special inhaler device and blister packs containing capsules of the medicine. You will load 2 capsules (one at a time) into the inhaler device each time you use the medicine. Pushing the handle of the device onto the mouthpiece will pierce the capsule and release the medicine into the inhaler.
Do not swallow a Maipedopa capsule. It is for use only in the Maipedopa inhaler device.
This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using Maipedopa.
Do not stop using Maipedopa suddenly after long-term regular use, or you could have unpleasant withdrawal symptoms (fever, confusion, muscle stiffness, changes in breathing and heart rate). Ask your doctor how to safely stop using this medicine.
Store at room temperature away from moisture and heat. Keep each capsule in the blister pack until you ready to load the inhaler device. Do not store capsules inside the device.
Throw away the device when your capsules run out. Always use the inhaler device that comes with each new prescription.
Uses of Maipedopa in details
Maipedopa is used to treat symptoms such as stiffness, tremors, spasms, and poor muscle control associated with Parkinson disease and parkinsonism-like symptoms caused by taking certain other drugs such as chlorpromazine, fluphenazine, perphenazine.
Maipedopa description
The naturally occurring form of dihydroxyphenylalanine and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonian disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. [PubChem]
Maipedopa dosage
Maipedopa Dosage
Generic name: Maipedopa 42mg
Dosage form: capsule
Medically reviewed on January 3, 2019.
Maipedopa capsules are for oral inhalation only and should be used only with the Maipedopa inhaler.
Important Administration Instructions
Maipedopa capsules are for oral inhalation only and should be used only with the Maipedopa inhaler. Maipedopa capsules must not be swallowed as the intended effect will not be obtained. Maipedopa capsules should be stored in their blister package and only removed immediately before use.
Recommended Dosage
Maipedopa should be taken when symptoms of an OFF period start to return.
The recommended dosage of Maipedopa is oral inhalation of the contents of two 42 mg capsules (84 mg) as needed, up to 5 times a day. The maximum dose per OFF period is 84 mg, and the maximum daily dosage is 420 mg. Maipedopa has been shown to be effective only in combination with carbidopa/Maipedopa.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
More about Maipedopa (Maipedopa)
- Maipedopa Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- Drug class: dopaminergic antiparkinsonism agents
Professional resources
- Maipedopa (FDA)
Related treatment guides
- Parkinson's Disease
Maipedopa interactions
See also:
What other drugs will affect Maipedopa?
Increased postural hypotension and possible reduced absorption with TCAs. Reduced effects with phenothiazines, butyrophenones, thioxanthenes and other antipsychotic agents; reserpine, papaverine, phenytoin, isoniazid. Reversal of effects of Maipedopa monotherapy with pyridoxine. Exacerbation of abnormal involuntary movements and possibly delayed absorption with anticholinergics. Additive hypotensive effects with antihypertensive agents. Increased CNS toxicity with methyldopa. Exacerbation of parkinsonian symptoms with metoclopramide.
Potentially Fatal: Increased risk of hypertensive crises with nonselective MAOIs. Increased risk of cardiac arrhythmias with cyclopropane or halogenated anaesthetics.
Maipedopa side effects
See also:
What are the possible side effects of Maipedopa?
The following serious adverse reactions are discussed below and elsewhere in the labeling:
- Falling Asleep During Activities of Daily Living and Somnolence
- Withdrawal-Emergent Hyperpyrexia and Confusion
- Hallucinations/Psychosis
- Impulse Control/Compulsive Behaviors
- Dyskinesia
- Bronchospasm in Patients with Lung Disease
- Glaucoma
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions in Study 1
Table 1 lists the adverse reactions that occurred in at least 2% of patients with Parkinson's disease who were treated with Maipedopa 84 mg and higher than placebo for OFF periods in Study 1. Study 1 was a double-blind, placebo-controlled study, in which 114 patients received Maipedopa 84 mg (two 42 mg capsules) for an average of 2 doses per day, to a maximum of 5 times a day, and 112 patients received placebo. Maipedopa-treated patients were 45-82 years of age (mean 63.5 years of age) and were predominantly male (72%) and white (94%). All patients were also treated with oral carbidopa/Maipedopa. The most common adverse reactions (≥ 5% and higher than placebo) in Study 1 were cough, nausea, upper respiratory tract infection, and sputum discolored.
| Adverse Reactions | Maipedopa 84 mg N=114 % | Placebo N=112 % |
|---|---|---|
| Respiratory, thoracic and mediastinal disorders | ||
| Cough | 15 | 2 |
| Sputum discolored | 5 | 0 |
| Nasal discharge discoloration | 2 | 0 |
| Oropharyngeal pain | 2 | 0 |
| Gastrointestinal disorders | ||
| Nausea | 5 | 3 |
| Vomiting | 3 | 0 |
| Infections and infestations | ||
| Upper respiratory tract infection | 6 | 3 |
| Nasopharyngitis | 3 | 2 |
| Bronchitis/pneumonia | 2 | 0 |
| Nervous system disorders | ||
| Dyskinesia | 4 | 1 |
| Headache | 2 | 0 |
| Injury, poisoning and procedural complications | ||
| Fall | 3 | 2 |
| Laceration | 2 | 0 |
| Skin abrasion | 2 | 0 |
| General disorders and administration site conditions | ||
| Chest discomfort | 2 | 0 |
| Investigations | ||
| Blood bilirubin increased | 2 | 0 |
| Red blood cell count decreased | 2 | 0 |
| Musculoskeletal and connective tissue disorders | ||
| Pain in extremity | 2 | 1 |
| Psychiatric disorders | ||
| Insomnia | 2 | 1 |
| Vascular disorders | ||
| Orthostatic hypotension/blood pressure decreased | 2 | 0 |
Adverse Reactions Leading to Discontinuation in Study 1
In Study 1, 6 of 114 patients (5%) in the Maipedopa 84 mg group and 3 of 112 patients (3%) in the placebo group discontinued because of adverse reactions. The most common of these adverse reactions was cough, which lead to discontinuation in 2% of patients in the Maipedopa 84 mg group and none in the placebo group.
Maipedopa contraindications
See also:
What is the most important information I should know about Maipedopa?
Monoamine oxidase (MAO) inhibitors and Maipedopa should not be given concomitantly and these inhibitors must be discontinued 2 weeks prior to initiating therapy with Maipedopa. Maipedopa is contraindicated in patients with known hypersensitivity to the drug and in narrow angle glaucoma.
Because Maipedopa may activate a malignant melanoma, it should not be used in patients with suspicious, undiagnosed skin lesions or a history of melanoma.
Active ingredient matches for Maipedopa:
List of Maipedopa substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Eldopal (Netherlands) | |
| Eldopar | |
| Eldopatec | |
| Eurodopa | |
| Helfo-Dopa | |
| Inbrija | |
| Insulamina | |
| Laradopa | |
| Larodopa | |
| Capsule; Oral; Levodopa 100 mg (Cambridge) | |
| Capsule; Oral; Levodopa 250 mg (Cambridge) | |
| Capsule; Oral; Levodopa 500 mg (Cambridge) | |
| Tablet; Oral; Levodopa 100 mg (Cambridge) | |
| Tablet; Oral; Levodopa 250 mg (Cambridge) | |
| Tablet; Oral; Levodopa 500 mg (Cambridge) | |
| Ledopa | |
| Levedopa | |
| Levocarbin (Peru) | |
| Levodopa (Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Belarus, Bolivia, Bosnia & Herzegowina, Bulgaria, Cambodia, China, Croatia (Hrvatska), Cuba, Czech Republic, Denmark, Estonia, Ethiopia, Finland, Georgia, Germany, Greece, Hong Kong, Hungary, Iceland, Indonesia, Ireland, Italy, Jamaica, Japan, Kazakhstan, Laos, Lithuania, Luxembourg, Malta, Mexico, Moldova, Netherlands, New Zealand, Norway, Oman, Paraguay, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Trinidad & Tobago, Turkey, Turkmenistan, United Kingdom, Uzbekistan, Venezuela) | |
| L-dopa powder | $ 15.19 |
| Levodopa powder | $ 7.31 |
| Levodopa 250 mg | |
| Lévodopa | |
| L-dopa powder | $ 15.19 |
| Levodopa powder | $ 7.31 |
| Levodopa 250 mg | |
| L-dopa powder | $ 15.19 |
| Levodopa powder | $ 7.31 |
| Levodopa 250 mg | |
| Levodopa - Beida Pharm (China) | |
| Levodopa Fu Seng (Taiwan) | |
| Levodopa-c | |
| Madopar-F (India) | |
| Madopar-F Levodopa 200mg, Benserazide50mg TAB / 10 (NPIL (Cognex)) | $ 1.11 |
| 10's (NPIL (Cognex)) | $ 1.27 |
| MADOPAR-F tab 10's (NPIL (Cognex)) | $ 1.11 |
| Majormet (Taiwan) | |
| Majormet 1000's | |
| Parda | |
| Rigakin (Netherlands) | |
| Sobiodopa | |
| Symblyopia (China) | |
| Syndpa Plus | |
| Syndpa Plus Carbidopa 25mg, Levodopa 100mg TAB / 10 | $ 0.26 |
| Syndpa Plus Carbidopa 25mg, Levodopa 100mg TAB / 10 | $ 0.26 |
| Veldopa (United Kingdom) | |
| Weldopa | |
See 82 substitutes for Maipedopa | |
References
- DailyMed. "CARBIDOPA; ENTACAPONE; LEVODOPA: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "levodopa". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "levodopa". http://www.drugbank.ca/drugs/DB01235 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Maipedopa are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Maipedopa. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
